2-(3′, 4′-Dimethoxybenzylidene)tetralone induces anti-breast cancer activity through microtubule stabilization and activation of reactive oxygen species. Issue 40 (5th April 2016)

• Record Type: Journal Article
• Authors: Gautam, Yashveer; Dwivedi, Sonam; Srivastava, Ankita; Hamidullah, ; Singh, Arjun; Chanda, D.; Singh, Jyotsna; Rai, Smita; Konwar, Rituraj; Negi, Arvind S.
• Is Part Of: RSC advances. Volume 6:Issue 40(2016)
• Page Start: 33369
• Page End: 33379
• Publication Date: 2016-04-05
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c6ra02663j
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : 2-Benzylidene tetralone derivatives are exhibited as potent anti-breast cancer agents through microtubule stabilization and induction of apoptosis through reactive oxygen species. Abstract : Breast cancer is a leading cause of women mortality worldwide. Diverse analogues of 2-benzylidene tetralone have been synthesized and evaluated for anti-cancer activity against a panel of cancer cell lines. Among these, compounds13, 15 and19 exhibited potent anti-cancer activity (IC50 = 1–3 μM) against human breast cancer cells, MDA-MB-231 and non-toxic towards non-malignant cell line, HEK-293. Compounds13, 15 and19 significantly stabilized tubulin polymerization and arrested cell cycle progression at G0/G1 phase instead of typical mitotic arrest at G2/M phase as observed in case of tubulin polymerization modulators suggesting induction of mitotic slippage followed by cell death. Further, mechanistic studies revealed that compound13 induced reactive oxygen species generation and apoptosis in breast cancer cells. Inhibition of ROS by N -acetyl-l -cysteine prevented compound13 induced cytotoxicity. Compound13 showed potent anti-cancer activity (74–79% tumour reduction) in syngeneic rat mammary tumour model without any adverse side effect. It was well tolerated up to 1000 mg kg −1 dose in acute oral toxicity. The identified lead molecule13 may further be optimized for better activity.